Logo

Innovent's Tyvyt (sintilimab) + Pemetrexed and Platinum CT Receives NMPA's Approval as 1L Therapy with Non-squamous Non-Small Cell Lung Cancer

Share this

Innovent's Tyvyt (sintilimab) + Pemetrexed and Platinum CT Receives NMPA's Approval as 1L Therapy with Non-squamous Non-Small Cell Lung Cancer

Shots:

  • The approval follows P-III ORIENT-11 study assessing Tyvyt (sintilimab) vs PBO + Almita (pemetrexed) and platinum CT in 397 participants in a ratio (2:1) as 1L therapy for advanced or recurrent nsqNSCLC
  • Results: Improvement in PFS- as assessed by IRC; mPFS (8.9 vs 5.0mos.); safety profile is consistent with previously reported studies with no new safety signals. At updated analysis after extended follow up- mOS (not reached vs 16.0 mos.)
  • Sintilimab is an innovative PD-1 inhibitor- jointly developed by Eli Lilly and Innovent. The approval marks the second indication for sintilimab in China

 ­ Ref: PRNewswire | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions